Business Context and Reporting Period
Company: Amgen Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 1998
Overview: Amgen is a global biotechnology company discovering, developing, manufacturing, and marketing human therapeutics. Its core commercial products are EPOGEN(R) (for anemia in dialysis patients), NEUPOGEN(R) (for neutropenia in chemotherapy patients), and INFERGEN(R) (for chronic hepatitis C). The company operates manufacturing facilities in the U.S., Puerto Rico, and the Netherlands, with a global sales force.
Key Financial Metrics (Year Ended Dec 31, 1998)
| Metric | 1998 | 1997 | 1996 |
|---|---|---|---|
| Total Revenues | $2,718.2 million | $2,401.0 million | $2,239.8 million |
| Product Sales | $2,514.4 million | $2,219.8 million | $2,088.2 million |
| Net Income | $863.2 million | $644.3 million | $679.8 million |
| Diluted EPS | $1.63 | $1.17 | $1.21 |
| Operating Cash Flow | $1,041.5 million | $902.9 million | $822.6 million |
| Long-Term Debt | $223.0 million | $229.0 million | $59.0 million |
| Cash & Equivalents | $201.1 million | $239.1 million | $169.3 million |
| Marketable Securities | $1,074.9 million | $787.4 million | N/A |
| Stockholders' Equity | $2,562.2 million | $2,139.3 million | $1,906.3 million |
Margins: Cost of sales was 13.7% of product sales in 1998. The effective tax rate was 29.5%.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 13% to $2.72 billion, driven primarily by a 19% increase in EPOGEN(R) sales ($1.38 billion) and a 6% increase in NEUPOGEN(R) sales ($1.12 billion).
- Profitability: Net income rose 34% to $863.2 million. This was significantly aided by a $23 million credit in Q4 1998 related to reduced uncertainty in the Johnson & Johnson arbitration liability, contrasting with a $157 million charge in 1997.
- Product Launch: INFERGEN(R) sales reached $15.8 million in its first full year on the market, a 365% increase over 1997.
- Capital Structure: The company increased long-term debt to $223 million (up from $59 million in 1996) via new issuances, while maintaining a strong cash position of over $1.2 billion including marketable securities.
- Share Repurchases: The company repurchased 28.7 million shares for $912.1 million in 1998, exceeding the 27.3 million shares repurchased in 1997.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary & Outlook
- EPOGEN(R): Growth is expected to continue due to higher dosing (driven by HCFA reimbursement policy changes) and population growth. However, the Clinton administration proposed a 10% cut in Medicare reimbursement, which could impact future sales.
- NEUPOGEN(R): Future growth depends on market penetration and new indications. Sales face pressure from cost containment and competition in the EU. Off-label use in AIDS treatment is declining due to new protease inhibitor therapies.
- Capital Expenditures: Anticipated spending of $300-$400 million in 1999 to expand global operations.
Risks and Contingencies
- Johnson & Johnson Arbitration: Ongoing disputes regarding "spillover" sales of erythropoietin. While Amgen won the primary arbitration in 1998, J&J is contesting the award of legal fees and challenging survey results for 1995-1998. Amgen has also filed a demand to terminate the license agreement.
- Regulatory & Reimbursement: Significant reliance on Medicare/Medicaid for EPOGEN(R). Changes in HCFA policies or reimbursement rates pose a material risk. NEUPOGEN(R) faces potential Medicare Part B coverage challenges.
- Year 2000 Compliance: The company is not yet fully compliant. Remediation is expected to cost $40-$60 million. Failure of suppliers or payors to be compliant could materially disrupt operations.
- Product Development: High uncertainty in clinical trials. Notable setbacks include the discontinuation of MGDF (platelet growth factor) due to antibody issues and mixed results for Leptin in obesity trials.
- Legal Proceedings: Active patent litigation with Biogen (regarding NEUPOGEN(R) and INFERGEN(R)) and Genentech. A securities class action lawsuit was filed in 1998 regarding alleged misrepresentations of sales growth.
Investor Verification Checklist
- Arbitration Status: Verify the final resolution of the Johnson & Johnson arbitration regarding legal fees and the 1995-1998 spillover liability.
- Reimbursement Policy: Monitor the outcome of the proposed 10% Medicare cut for EPOGEN(R) and any changes to HCFA hematocrit guidelines.
- Year 2000 Readiness: Confirm the status of remediation for critical manufacturing and financial systems and the compliance status of key suppliers.
- Patent Litigation: Track the progress of the Biogen and Genentech patent infringement suits, which could impact NEUPOGEN(R) and INFERGEN(R) sales.
- Product Pipeline: Assess the clinical trial results for NESP (Novel Erythropoiesis Stimulating Protein) and STEMGEN(R), which are critical for future growth beyond current core products.